Main subject characteristics at baseline by DNA index (n = 93)
| Diploid (n = 35) | Aneuploid (n = 58) | P* | ||||
|---|---|---|---|---|---|---|
| Age (median), y | ||||||
| ≤63 | 23 (65.7)† | 27 (46.6) | 0.09 | |||
| >63 | 12 (34.3) | 31 (53.4) | ||||
| Sex | ||||||
| Male | 27 (77.1) | 48 (82.8) | 0.6 | |||
| Female | 8 (22.9) | 10 (17.2) | ||||
| Smoking habit | ||||||
| Nonsmoker | 9 (25.7) | 13 (22.4) | 0.5 | |||
| Former smoker | 10 (28.6) | 24 (41.4) | ||||
| Current smoker | 16 (45.7) | 21 (36.2) | ||||
| Tumor stage | ||||||
| pTa | 22 (62.9) | 32 (55.2) | 0.5 | |||
| pT1 | 13 (37.1) | 26 (44.8) | ||||
| Tumor grade | ||||||
| G1 | 19 (54.3) | 19 (32.8) | 0.1 | |||
| G2 | 13 (37.1) | 33 (56.9) | ||||
| G3 | 3 (8.6) | 6 (10.3) | ||||
| Tumor history | ||||||
| First event | 19 (54.3) | 16 (27.6) | 0.02 | |||
| Recurrent tumor | 16 (45.7) | 42 (72.4) | ||||
| Treatment | ||||||
| Fenretinide (4-HPR) | 15 (42.9) | 33 (56.9) | 0.2 | |||
| Control | 20 (57.1) | 25 (43.1) | ||||
| Previous intravesical treatment | ||||||
| None | 7 (20.0) | 1 (1.7) | 0.01 | |||
| Bacillus Calmette-Guèrin | 15 (42.9) | 35 (60.3) | ||||
| Chemotherapy | 13 (37.1) | 22 (37.9) | ||||